Related Experiment Video
Updated: Feb 23, 2026
19:15
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
88.2K
Do trials reduce uncertainty? Assessing impact through cumulative meta-analysis of neonatal RCTs.
S C Hay1,2, H Kirpalani3, C Viner4
1Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Summary
The latest randomized controlled trials (RCTs) often fail to significantly impact systematic reviews. New RCTs rarely change effect estimates or statistical significance, suggesting a need to prioritize under-researched topics.
Area of Science:
- Medical research methodology
- Evidence-based medicine
- Clinical trial analysis
Background:
- Systematic reviews (SRs) synthesize evidence from randomized controlled trials (RCTs).
- The incremental impact of new RCTs on existing SRs is not well quantified.
- Cochrane Neonatal Reviews provide a relevant dataset for evaluating this impact.
Purpose of the Study:
- To assess the impact of the latest RCT on systematic reviews in Cochrane Neonatal Reviews.
- To determine factors influencing the impact of new RCTs on meta-analytic estimates.
Main Methods:
- Selected meta-analyses from Cochrane Neonatal Reviews based on the latest RCT.
- Employed cumulative meta-analysis to track estimate changes as new trials were added.
- Used multivariable logistic regression to identify predictors of study impact.
Main Results:
- A majority of latest RCTs did not substantially narrow confidence intervals (CIs) or change effect estimates.
- Only a small percentage of RCTs altered the directionality or statistical significance of primary outcomes.
- The ability of an RCT to narrow the CI was inversely related to the number of prior RCTs.
Conclusions:
- The latest RCTs frequently have a limited impact on the overall evidence synthesis in SRs.
- Consideration should be given to prioritizing under-researched topics for future RCTs.
- Formal assessment of optimal information size is recommended for power calculations in new RCTs.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
500
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
500
01:52Regression Toward the Mean
7.2K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
7.2K
01:16Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
01:11Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
01:07Teratogenicity
4.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.3K
01:29Drug Dosing: Infants and Children
373
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
373